๐Ÿ”ฌDeep Research

ALXO โ€” Alx Oncology Holdings Inc ยท catalysts, narrative & risks

ยท16 sourcesALXO forecast โ†’

ALX Oncology Holdings Inc. (ALXO) โ€” Research Summary

As of 2026-10-04. The following is a synthesis of provided sources for informational purposes and does not constitute investment advice.

Company & Current Market Snapshot

ALX Oncology Holdings Inc. (Nasdaq: ALXO) is a U.S.-listed, clinical-stage immuno-oncology company [background, 12, 13]. Its lead candidate is evorpacept (a CD47-blocking biologic) and its second candidate is ALX2004 (an EGFR-targeted antibody-drug conjugate) [5][12][13].


AI-assisted research from the K3vl4r desk โ€” not personalized investment advice. More research โ†’